Zevra Therapeutics
ZVRA
70 hedge funds and large institutions have $98.4M invested in Zevra Therapeutics in 2021 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 17 closing their positions.
348% more capital invested
Capital invested by funds: $22M → $98.4M (+$76.4M)
123% more call options, than puts
Call options by funds: $30.6M | Put options by funds: $13.7M
112% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 17
37% more funds holding
Funds holding: 51 → 70 (+19)
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
14.4% more ownership
Funds ownership: 8.26% → 22.66% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20.5M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$7.77M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.31M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$4.74M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.96M |
| 2 |
Jane Street
New York
|
-$1.72M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.39M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$678K |
| 5 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$615K |
ZVRA Hedge Fund Activity: Q2 2021 in Review
70 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2021, worth a combined $98.4M — up 348% from $22M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ZVRA positions and 17 closed out — a net gain of 19 holders — while 12 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $20.5M. The largest seller was Millennium Management, exiting entirely with an estimated $1.96M sold.
- 70 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2021, up from 51 in Q1 2021.
- Funds reported $98.4M of Zevra Therapeutics stock for Q2 2021, up 348% quarter-over-quarter.
- 36 funds opened new Zevra Therapeutics positions in Q2 2021 and 17 closed out, a net change of +19 holders.
- The largest Zevra Therapeutics buyer in Q2 2021 was BlackRock, an estimated $20.5M added.
- The largest Zevra Therapeutics seller in Q2 2021 was Millennium Management, an estimated $1.96M sold.
Based on aggregated 13F filings for Q2 2021.